GBX Summits ™ works in conjunction with some of the world's most prominent leaders and visionaries across a variety of key industries in order to produce cutting edge programmes that simulate, educate and accelerate innovation.
Steering Committee And Speaker Faculty At A Glance
Dr. Gottschalk is Group Vice President, Purification Technologies, with a global responsibility for bioseparation products at Sartorius Stedim Biotech. He worked in different capacities for Bayer Health Care from 1991-2004 and became head of the GMP protein purification facility in Wuppertal.
Prof. Dr. Thomas Herget is currently Head of Processing Technologies within the Merck Millipore process solutions division of Merck KGaA, where he develops new methods and materials for bioprocessing. He is also a medical professor at the University of Mainz and a biochemistry professor at the TU Darmstadt. He has received several awards, submitted 25 patents and authored more than 50 peer-reviewed papers. From 2004-2010, Prof. Dr. Thomas Herget served as the Director, New Technology Evaluation within Merck KGaA’s Chemicals R&D division. In that role, he ran laboratories in Darmstadt (Germany) and oversaw the R&D activities of Novagen (Madison) and Calbiochem (San Diego). In 2000, he joined the Munich-based Axxima Pharmaceuticals AG (now GPC Biotech), a biotech startup founded by Prof. Axel Ullrich, to focus on the development of protein kinase inhibitors in infectious diseases.
Ted Torphy, PhD, has 30 years’ experience and a successful record in both small-molecule and large-molecule drug discovery. In addition, Dr. Torphy is a recognized leader in bringing open innovation to the pharmaceutical industry.
Dr. Boon received his Ph.D. in Biochemistry at the University of Amsterdam. He also carried out post-doctoral positions at University of Amsterdam at the Department of Anatomy and Embryology and at the Department of Clinical Epidemiology. Thereafter he was one of the founders of PanGenetics where he was responsible for project management and animal studies. Since the merger between PanGenetics and Tanox Inc. in Houston, he had the position of VP Preclinical in which he was world-wide responsible for preclinical safety assessments and animals studies for the Tanox group. Dr. Boon has performed antibody therapy for immunoinflammatory diseases both in murine and non-human primate disease models and healthy non-human primates. Thereafter Dr. Boon was one of the founders of MacroZyme BV and for 2 years Director of Preclinical R&D of MacroZyme BV, where he was responsible for a small molecule project in the metabolic field and various potential protein-based therapeutic molecules. In 2003 he was one of the founders of Bioceros BV where he currently holds a position of Chief Scientific Officer (CSO). In addition he held a position as CSO for 4AZA Bioscience NV and VP Preclinical (ad interim) for PanGenetics BV until the end of 2006. He has extensive experience in molecular and cellular immunology and in therapeutic antibody development and has been involved in the trajectory of preclinical preparation and design of First into Man studies using therapeutic antibodies. Dr. Boon is author/co-author of over 200 papers in international scientific journals in the field of medical biotechnology.
Dr. Rod MacKenzie, Ph.D serves as Senior Vice President and Head of Worldwide Research for PharmaTherapeutics R&D at Pfizer Inc. and has been its Groton site leader since April 25, 2012 and has been the President of PharmaTherapeutics Research & Development since May 2010.
Eric de La Fortelle is Global Head, External Research and Technologies, for Roche Partnering in Basel, Switzerland. He heads a group with a global mandate to find partners, establish contracts and manage alliances with companies offering innovative technologies for every stage of product discovery, development and lifecycle. Such technologies include discovery technologies (assays, small molecules, biologics, RNA, cell therapies) as well as bioinformatics, biomarkers, safety, and formulation/delivery technologies. Eric is a scientist by training, with contributions in the field of structure-based drug design (determination of 3D structures of protein targets by X-ray crystallography).